Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) often relapses under epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment due to resistant cell subpopulations.
• Understanding resistance mechanisms is crucial for developing effective long-term cancer therapies.

Purpose of the Study:

• To investigate the efficacy of sorafenib in overcoming EGFR-TKI resistance in NSCLC.
• To elucidate the molecular mechanisms by which sorafenib impacts resistant and sensitive NSCLC cells.

Main Methods:

• Utilized a DNA barcoding approach to track cell populations.
• Employed various xenograft and allograft models to assess therapeutic combinations.
• Analyzed molecular pathways including MAPK-interacting kinase (MKNK) and signal transducer and activator of transcription 3 (STAT3) phosphorylation.

Main Results:

• Sorafenib selectively eliminated EGFR-TKI-resistant NSCLC cells while sparing sensitive cells.
• Sorafenib demonstrated activity against multiple EGFR-TKI resistance mechanisms.
• The combination of sorafenib and EGFR-TKI delayed tumor growth and promoted inflammatory cell recruitment.

Conclusions:

• Sorafenib can prolong the efficacy of EGFR-TKIs in NSCLC by targeting the emergence of resistant cells.
• Sorafenib's mechanism involves early inhibition of MKNK and STAT3 phosphorylation, followed by MCL1 and EGFR downregulation.
• Combination therapy holds promise for improving long-term outcomes in EGFR-TKI treated NSCLC patients.